Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...
Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...
In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward ...
Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. MRNA has guided for 2025 revenues of $1.5B-$2.5B which doesn't seem to have ...
As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.
Moderna launched RSV vaccine mResvia in 2024 as the third-to-market product behind GSK and Pfizer vaccines. However, the firm's pipeline progress could lead to 2025-27 launches for a covid/flu ...
The crash in MRNA stock comes after the company slashed its outlook for 2024 and 2025 sales and also announced an expanded ...
"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...
The Cambridge-based company said it expects 2025 revenue of between $1.5 billion to $2.5 billion, down from its previous projection of between $2.5 billion and $3.5 billion.